Presented By Steven Park at 2016 ASCO Annual Meeting

Slides:



Advertisements
Similar presentations
Allogeneic Transplant Following Brentuximab Vedotin Treatment in Patients with Relapsed or Refractory CD30+ Lymphomas Illidge T et al. Proc ASH 2011;Abstract.
Advertisements

Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
Slide 1 Presented By Susan Chang at 2014 ASCO Annual Meeting.
Presented By Anthony Cmelak at 2014 ASCO Annual Meeting
Presented By Raymond Huang at 2014 ASCO Annual Meeting
LaCasce A et al. Proc ASH 2014;Abstract 293.
Phase Difference = Phase Difference = 0.05.
Results of a Phase II Trial of Brentuximab Vedotin as First Line Salvage Therapy in Relapsed/Refractory HL Prior to AHCT Chen RW et al. Proc ASH 2014;Abstract.
GROUP 5 Monoclonal Antibodies for Cancer Treatment.
Frontline Therapy with Brentuximab Vedotin Combined with ABVD or AVD in Patients with Newly Diagnosed Advanced Stage Hodgkin Lymphoma Younes A et al. Proc.
Randomized Comparison of Ibrutinib Versus Ofatumumab in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Results From the.
Randomized Comparison of Adjuvant Aromatase Inhibitor Exemestane plus Ovarian Function Suppression vs Tamoxifen plus Ovarian Function Suppression in Premenopausal.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with 131I-refractory differentiated thyroid.
Slide 1 Presented By Pierre-Yves Dietrich at 2014 ASCO Annual Meeting.
Immediate vs. deferred initiation of androgen deprivation therapy in prostate cancer patients with PSA-only relapse. An observational follow-up study Presented.
A Phase 2 Study of Single-Agent Brentuximab Vedotin for Front- Line Therapy of Hodgkin Lymphoma in Patients Age 60 Years and Above: Interim Results Yasenchak.
Randomized Phase III US/Canadian Intergroup Trial (SWOG S9704) Comparing CHOP ± R for Eight Cycles to CHOP ± R for Six Cycles Followed by Autotransplant.
Slide 1 Presented By Christian Hinrichs at 2014 ASCO Annual Meeting.
Brentuximab Vedotin in Combination with RCHOP as Front-Line Therapy in Patients with DLBCL: Interim Results from a Phase 2 Study Yasenchak CA et al. Proc.
基 督 再 來 (一). 經文: 1 你們心裡不要憂愁;你們信神,也當信我。 2 在我父的家裡有許多住處;若是沒有,我就早 已告訴你們了。我去原是為你們預備地去 。 3 我 若去為你們預備了地方,就必再來接你們到我那 裡去,我在 那裡,叫你們也在那裡, ] ( 約 14 : 1-3)
Presented By Shin Fujita at 2016 ASCO Annual Meeting
Presented By Michele Cavo at 2016 ASCO Annual Meeting
Presented By Lorenz Trumper at 2016 ASCO Annual Meeting
Savage KJ et al. Proc ASH 2015;Abstract 579.
Updated Efficacy and Safety Data from the AETHERA Trial of Consolidation with Brentuximab Vedotin after Autologous Stem Cell Transplant (ASCT) in Hodgkin.
Shustov AR et al. Proc ASH 2010;Abstract 961.
Securing the cure in resectable lung cancer
Nivolumab in Patients (Pts) with Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL): Clinical Outcomes from Extended Follow-up of a Phase 1 Study.
Presented By Mette Van Ramshorst at 2017 ASCO Annual Meeting
Highlights: Myeloma Oral Session
Near Complete Response in a Patient with Classical Hodgkin Lymphoma Treated with Brentuximab Vedotin Concurrent with Radiation Therapy - DOI: /
Presented By Marco Colleoni at 2017 ASCO Annual Meeting
Presented By Luca Malorni at 2017 ASCO Annual Meeting
continued on next slide
Presented By Jason Fangusaro at 2017 ASCO Annual Meeting
Presented By Amrita Krishnan at 2016 ASCO Annual Meeting
Post-autologous Transplant Therapy for Hodgkin Lymphoma
                                                                                                                                                                                                                                                
Learning Goals. Harnessing the Immune System: Mechanism of Action of Immunotherapies in B-Cell Malignancies.
continued on next slide
continued on next slide
Presented By James Rubenstein at 2016 ASCO Annual Meeting
Updates in Hodgkin Lymphoma
Peripheral T-Cell Lymphoma in 2013
A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.
Advances in Lymphoma.
Emerging Targeted Agents for Relapsed/Refractory Non-Hodgkin Lymphoma
Ansell SM et al. Proc ASH 2012;Abstract 798.
The Emerging Role of Immunotherapy in Hodgkin Lymphoma
Слайд-дәріс Қарағанды мемлекеттік техникалық университеті
.. -"""--..J '. / /I/I =---=-- -, _ --, _ = :;:.
Emerging Frontline Treatments for Patients With Hodgkin Lymphoma
Updated Efficacy and Safety Data from the AETHERA Trial of Consolidation with Brentuximab Vedotin after Autologous Stem Cell Transplant (ASCT) in Hodgkin.
Presented By Mathias Rummel at 2016 ASCO Annual Meeting
II //II // \ Others Q.
I1I1 a 1·1,.,.,,I.,,I · I 1··n I J,-·
Results of a Multicenter Phase II Trial of Brentuximab Vedotin as Second-Line Therapy before Autologous Transplantation in Relapsed/Refractory Hodgkin.
Gordon LI et al. Proc ASH 2010;Abstract 415.
Forero-Torres A et al. Proc ASH 2011;Abstract 3711.
Changing the Paradigm of Treatment in Patients With Hodgkin Lymphoma
Anas Younes, M.D. Memorial Sloan Kettering Cancer Center
. '. '. I;.,, - - "!' - -·-·,Ii '.....,,......, -,
continued on next slide
Presented By Joshua Richter at 2016 ASCO Annual Meeting
Hodgkin’s lymphoma stage I/II Untreated, age 15-70
Presented By Andrew Evens at 2016 ASCO Annual Meeting
by Andrew M. Evens, and Lale Kostakoglu
continued on next slide
624. Randomized Phase II Trial of Adjuvant Autologous Tumor Cell Vaccine (FANG™) for High Risk Stage III/IV Ovarian Cancer: Preliminary Results    Molecular.
Presentation transcript:

Presented By Steven Park at 2016 ASCO Annual Meeting A Phase II Trial of ABVD followed by Brentuximab Vedotin Consolidation Therapy in Limited Stage Non-bulky Hodgkin Lymphoma (LCCC 1115) Presented By Steven Park at 2016 ASCO Annual Meeting

Presented By Steven Park at 2016 ASCO Annual Meeting Slide 2 Presented By Steven Park at 2016 ASCO Annual Meeting

Presented By Steven Park at 2016 ASCO Annual Meeting Slide 3 Presented By Steven Park at 2016 ASCO Annual Meeting

Presented By Steven Park at 2016 ASCO Annual Meeting Slide 4 Presented By Steven Park at 2016 ASCO Annual Meeting

Presented By Steven Park at 2016 ASCO Annual Meeting Slide 5 Presented By Steven Park at 2016 ASCO Annual Meeting

Presented By Steven Park at 2016 ASCO Annual Meeting Slide 6 Presented By Steven Park at 2016 ASCO Annual Meeting

Presented By Steven Park at 2016 ASCO Annual Meeting Slide 7 Presented By Steven Park at 2016 ASCO Annual Meeting

Presented By Steven Park at 2016 ASCO Annual Meeting Slide 8 Presented By Steven Park at 2016 ASCO Annual Meeting

Presented By Steven Park at 2016 ASCO Annual Meeting Slide 9 Presented By Steven Park at 2016 ASCO Annual Meeting

Presented By Steven Park at 2016 ASCO Annual Meeting Slide 10 Presented By Steven Park at 2016 ASCO Annual Meeting

Presented By Steven Park at 2016 ASCO Annual Meeting Slide 11 Presented By Steven Park at 2016 ASCO Annual Meeting

Presented By Steven Park at 2016 ASCO Annual Meeting Slide 12 Presented By Steven Park at 2016 ASCO Annual Meeting

Presented By Steven Park at 2016 ASCO Annual Meeting Slide 13 Presented By Steven Park at 2016 ASCO Annual Meeting

Presented By Steven Park at 2016 ASCO Annual Meeting Slide 14 Presented By Steven Park at 2016 ASCO Annual Meeting

Presented By Steven Park at 2016 ASCO Annual Meeting Slide 15 Presented By Steven Park at 2016 ASCO Annual Meeting

Presented By Steven Park at 2016 ASCO Annual Meeting Slide 16 Presented By Steven Park at 2016 ASCO Annual Meeting

Presented By Steven Park at 2016 ASCO Annual Meeting Slide 17 Presented By Steven Park at 2016 ASCO Annual Meeting

Presented By Steven Park at 2016 ASCO Annual Meeting Slide 18 Presented By Steven Park at 2016 ASCO Annual Meeting